Skip to content

Study on the effect and mechanism of platelet-rich plasma in prevention and treatment of residual symptoms after percutaneous foraminoscopy for lumbar disc herniation

Study on the effect and mechanism of platelet-rich plasma in prevention and treatment of residual symptoms after percutaneous foraminoscopy for lumbar disc herniation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082577
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-15
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

control group:PRP was not given during or after PETD
PRP1 group:In PRP1 group, 4 ml of PRP + 2 ml of thrombin were injected into the diseased disc and around the nerve root before the end of PETD
PRP2 group:In PRP2 group, 4 ml of PRP + 2 ml of thrombin were injected into the lateral recess of the affected side of the operative spinal segment on the 5th day after PETD
PRP3 group:In PRP3 group, 4 ml of PRP + 2 ml of thrombin were injected into the diseased disc and around the nerve root before the end of PETD,and 4 ml of PRP + 2 ml of thrombin were injected into th

Sponsors

Nanchong psychosomatic hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Age between 30 and 65 years; ? Low back pain with unilateral radiating ache in underbody; L4/5 or L5/S1 interspinous and paravertebral tenderness, ASLR test (+), VAS =5; Lumbar disc herniation was confirmed by MRI or CT ; ? With a poor outcome of conservative treatment; ? Tolerance to anesthesia and surgery; ? With complete data, voluntary participation in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: ? A history of lumbar surgery; ? Lumbar disc herniation with calcification or bone compression; ? Lumbar instability, spondylolisthesis or stenosis; ? The underlying disease cannot tolerate surgery; ?Tuberculosis, tumor, infection.

Design outcomes

Primary

MeasureTime frame
Oswestry disability index, ODI;visual analogue scale,VAS;CT grading of epidural fibrosis/adhesion CT grading;

Secondary

MeasureTime frame
prostaglandin E2,PGE2;histamine,HA;5-hydroxy-tryptamine,5-HT;

Countries

China

Contacts

Public ContactGuo-qiang Wang

Nanchong psychosomatic hospital

249280624@qq.com+86 158 8263 4550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026